And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to catch up on some reading, putter around the Pharmalot grounds, and take a nap or two. And what about you? Have you booked your summer getaway yet? You can still make plans. Meanwhile, this is a lovely time of year to enjoy the great outdoors, curl up with an ebook, or make time for someone special. Those of you tracking current events — and feeling mischievous — might want to compare the type of rats in Baltimore with those in Washington. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you after our own break — we are off next week. Ta-ta. …

The Trump administration plan to let Americans legally import cheaper prescription drugs from Canada is causing concern among Canadians who fear it could cause shortages of some medications, the Associated Press reports. Moreover, officials were surprised because they say they weren’t consulted about a possible influx of U.S. drug buyers. Health Minister Ginette Petitpas Taylor’s office said in a statement that, “while we’re aware of ongoing state-led initiatives to import Canadian drugs, we weren’t consulted on specifics.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy